INTRODUCTION AND OBJECTIVES: The management of testicular cancer requires a complex multimodal therapeutic approach. Despite the availability of regularly updated national and international guidelines on testicular cancer, treatment still differs between the institutions probably affecting the patients' outcome. Our study aims to investigate frequently occurring errors regarding the diagnosis and therapy of testicular cancer in consideration of the current EAU guidelines.
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METHODS: We performed a retrospective analysis including 129 patients diagnosed with testicular cancer that were referred to our department between 09/2015 and 10/2016. Patients' age, histology, clinical stage, IGCCCG risk classification, treatment (surveillance, chemotherapy, radiotherapy, surgery) and follow-up were investigated and compared to the EAU guidelines' recommendations.
RESULTS: Of the eligible 129 patients, 34 (26%) patients displayed a non-guideline concordant care. The most common error was undertreatment (47%), mostly due to missing chemotherapy cycles. Modified treatment and overtreatment occurred in 20% and 16% respectively, while inappropriate treatment (9%) and misdiagnosis (6%) were rarely seen (Table 1 ). In secondary treated patients, non-guideline concordant therapy was observed more frequently compared to those patients receiving primary therapy (59% vs. 41 %). Almost all patients (93%) receiving a non-guideline concordant therapy suffered a relapse in contrast to 67% of patients that were treated according to the EAU guidelines.
CONCLUSIONS: Non-adherence to the current EAU guidelines on testicular cancer appears to be a major problem in various testicular cancer treating institutions. In our study, the most frequent error was undertreatment, followed by modified treatment and overtreatment. Inappropriate therapy leads to a higher relapse rate and morbidity associated with a worse curative outcome. INTRODUCTION AND OBJECTIVES: Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) is rarely performed in patients with advanced germ cell tumors (GCT) and elevated serum tumor markers (STM). Few studies have assessed the therapeutic benefit of PC-RPLND in the setting of elevated STM.
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METHODS: From 2001 to 2014, 63 patients with elevated STM (alpha-fetoprotein ¼15.0 ng/mL and/or human chorionic gonadotropin ¼2.2 IU/L) underwent PC-RPLND. We evaluated associations between patient characteristics, histology, and cancer-specific survival (CSS) using descriptive statistics and univariable Cox regression models.
RESULTS: Median age at the time of RPLND was 28 years (IQR 22, 37) . Sixteen patients (25%) received two or more courses of chemotherapy prior to RPLND. RP histology revealed viable cancer in 20 patients (32%), teratoma only in 24 (38%), and fibrosis/necrosis only in 19 (30%). Viable cancer was more common among patients treated with second-line chemotherapy than those receiving only first-line chemotherapy (63% vs. 21%, p¼0.004) and in those with rising STM at RPLND compared with those with stable/declining STM levels (73% vs. 19%, p¼0.001). Concordance rates between retroperitoneal and extraretroperitoneal sites were 100% for fibrosis, 67% for teratoma, and 43% for viable cancer. Five-year CSS was 83% (95% CI 69-91%) during a median follow-up of 4.5 years for survivors. Persistent STM elevation after RPLND was associated with worse CSS (HR 9.73; 95% CI 2.95-32.07; p<0.001). This study is limited by retrospective data collection and small sample size.
CONCLUSIONS: Our findings showed the potential curative benefit of bilateral PC-RPLND and resection of all residual ERP diseases in GCT patients with elevated STM. This suggests that postchemotherapy surgery should be considered in a subset of patients with low and stable STM levels after first or second-line chemotherapy in order to possibly avoid the long-term toxicity of additional salvage chemotherapy. . 197, No. 4S, Supplement, Monday, May 15, 2017 
Source of

